Eli Lilly | LLY - Zinsaufwendungen Für Schuld

Aktienkurs
883.96
Täglich Wechseln
-33.69 -3.67%
Monatlich
-3.53%
Jährlich
-0.07%
Q2 Prognose
865.04




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Abbott USD 68M 26M 2026-03
ALKERMES USD 12.28M 7.63M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Baxter International USD 58M 14M 2025-09
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 432M 48M 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Drreddys Laboratories INR 944M 127M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
J&J USD 43M 25M 2026-03
Medtronic USD 181M 0 2025-12
Merck USD 412M 85M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Novartis USD 281M 8M 2025-09
Novo Nordisk DKK 1.53B 3.43B 2025-09
Perrigo USD 10.08B 10.04B 2025-09
Pfizer USD 711M 59M 2025-12
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 10.67M 636K 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
Sanofi EUR -25M 99.78M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Zoetis USD 57M 1000K 2025-12